Dr.ย Junย Zhu
Bachelor of Medicine (Clinical Medicine), Third Military Medical University; Doctoral Training, Hadassah Medical Center
Chief Physician, Department of Lymphoma Medical Oncology
corporate_farePeking University Cancer Hospital, Beijing
Jun Zhu
Bachelor of Medicine (Clinical Medicine), Third Military Medical University; Doctoral Training, Hadassah Medical Center
Prof. Jun Zhu is a Chief Physician and doctoral supervisor in the Department of Lymphoma Medical Oncology at Peking University Cancer Hospital, Beijing โ one of China's foremost dedicated lymphoma treatment centres. He has over 40 years of clinical experience in medicine and more than 25 years of focused specialisation in lymphoma diagnosis, treatment, and translational research.
Prof. Zhu graduated in clinical medicine from the Third Military Medical University in 1984 and subsequently worked at the PLA General Hospital (301 Hospital) in haematology and bone marrow transplantation. From 1994 to 1997, he worked and completed doctoral-level training in bone marrow transplantation at Hadassah Medical Center, Hebrew University of Jerusalem, Israel. Since 1998, he has been based at Peking University Cancer Hospital, where he led the lymphoma department for over two decades. His department is recognised as one of China's earliest and largest specialised lymphoma treatment centres, offering multidisciplinary care pathways, haematopoietic stem cell transplantation, and cellular immunotherapy. Prof. Zhu has published over 92 SCI papers as first or corresponding author in journals including Lancet Haematology, Annals of Oncology, Blood, and Nature Medicine, and has led or participated in over 200 domestic and international new-drug clinical trials.
CancerFax can coordinate medical record review, case preparation, and consultation support for international patients seeking an opinion from Prof. Jun Zhu at Peking University Cancer Hospital.
Why Consider Prof. Jun Zhu?
Prof. Jun Zhu combines deep lymphoma clinical expertise with a record of translational research, guideline authorship, and multi-drug clinical trial leadership. For patients with lymphoma โ particularly relapsed or refractory disease โ he represents access to one of China's most experienced lymphoma specialists.
Areas of Specialisation
Focused expertise in lymphoma diagnosis, treatment, translational research, and advanced cellular therapies
Prof. Jun Zhu specialises in the full spectrum of lymphoma management, from initial diagnosis through to treatment of relapsed or refractory disease. His clinical work covers Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell and T-cell lymphoma subtypes, and cases requiring advanced therapies including CAR-T cell therapy and autologous stem cell transplantation.
Hodgkin & Non-Hodgkin Lymphoma
Comprehensive diagnostic and treatment planning for all major lymphoma subtypes, from newly diagnosed to complex relapsed or refractory presentations.
- arrow_rightFirst-line and relapsed or refractory treatment planning
- arrow_rightMultidisciplinary staging and response assessment
- arrow_rightTreatment sequencing incorporating novel agents
- arrow_rightB-cell lymphoma including DLBCL, follicular, and mantle cell lymphoma
- arrow_rightT-cell and peripheral T-cell lymphoma
- arrow_rightChronic lymphocytic leukaemia and small lymphocytic lymphoma
- arrow_rightGastrointestinal and extranodal lymphoma
Advanced Cellular & Targeted Therapies
Novel treatment approaches for eligible lymphoma patients, including CAR-T cell therapy, BTK inhibitors, bispecific antibodies, and antibody-drug conjugates.
- arrow_rightCD19-directed CAR-T cell therapy for relapsed or refractory B-cell lymphoma
- arrow_rightPatient eligibility evaluation for cellular immunotherapy
- arrow_rightPost-CAR-T monitoring and toxicity management
- arrow_rightBTK inhibitor-based therapy including zanubrutinib
- arrow_rightPI3K inhibitor protocols
- arrow_rightAntibody-drug conjugates for eligible lymphoma subtypes
- arrow_rightBispecific and multispecific antibody therapy
Autologous Stem Cell Transplantation
Haematopoietic stem cell transplantation for eligible lymphoma patients, supported by one of China's largest dedicated lymphoma transplantation programmes.
- arrow_rightPatient selection, conditioning, and transplantation planning for lymphoma
- arrow_rightPost-transplant monitoring and supportive care
- arrow_rightIntegration with salvage therapy for relapsed disease
Procedures & Treatments
Clinical services and treatment approaches at Peking University Cancer Hospital
Prof. Zhu's department offers the full range of lymphoma treatment approaches within a multidisciplinary framework, from standard first-line chemotherapy through to advanced cellular therapies and clinical trial access.
Lymphoma Medical Oncology
Medical OncologyStandard and advanced systemic treatment for all major lymphoma subtypes including chemotherapy, immunotherapy, and maintenance therapy protocols.
Targeted Therapy for Lymphoma
Targeted TherapyMolecularly guided targeted agent selection and treatment planning for lymphoma subtypes with actionable targets.
Cellular Immunotherapy & Transplantation
TransplantCAR-T cell therapy and autologous haematopoietic stem cell transplantation for eligible lymphoma patients.
Multidisciplinary Lymphoma Care
MultidisciplinaryIntegrated team-based treatment planning for complex lymphoma presentations, involving oncology, haematology, radiology, and pathology.
Second Opinion Consultation
Second OpinionIndependent expert review of lymphoma diagnosis, staging, pathology, and treatment plan.
Research & Publications
Over 92 SCI papers and 200+ clinical trials in lymphoma
Prof. Zhu is one of China's most prolific lymphoma researchers. He has published over 92 SCI papers as first or corresponding author in leading journals and participated in more than 200 domestic and international new-drug clinical trials. His translational research has shaped treatment guidelines and accelerated the introduction of novel lymphoma therapies in China.
Prof. Zhu's department is an active centre for lymphoma clinical trials. CancerFax can coordinate eligibility assessment and case review for patients interested in accessing novel therapies or clinical trials at Peking University Cancer Hospital.
Education & Training
Prof. Zhu's training spans Chinese military medical education, haematology and bone marrow transplantation practice, and an internationally based doctoral training period at Hadassah Medical Center, Hebrew University of Jerusalem, Israel.
Clinical Experience
Prof. Zhu has spent over 25 years at Peking University Cancer Hospital following early career training in haematology and transplantation at the PLA General Hospital and an international fellowship in Israel. He led the Department of Lymphoma Medical Oncology for over two decades before his current role as Chief Physician.
Languages & International
Prof. Jun Zhu conducts consultations in Chinese (Mandarin). English is used in his academic and international research work; consultation availability in English should be confirmed through the hospital or via CancerFax coordination.
CancerFax can coordinate professional medical interpreter support for international patients, ensuring clear communication throughout the consultation process.
CancerFax can coordinate professional medical interpreter support for international patients consulting in English, Arabic, Russian, or other languages.
How CancerFax Helps You Access Dr. Jun Zhu
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Jun Zhu's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Jun Zhu's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Jun Zhu before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Jun Zhu's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Jun Zhu's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Jun Zhu's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Jun Zhu
Prof. Jun Zhu specialises exclusively in lymphoma, including Hodgkin lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, chronic lymphocytic leukaemia, and relapsed or refractory lymphoma. Lymphoma is the sole focus of his department at Peking University Cancer Hospital.
CancerFax can coordinate medical record review, case preparation, and consultation support for international patients seeking an opinion from Prof. Jun Zhu at Peking University Cancer Hospital, subject to hospital availability and case acceptance. CancerFax can also arrange interpreter support and assist with logistics for patients travelling to Beijing.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review the documents, prepare a structured case summary, and coordinate the next steps with the hospital, subject to availability. We manage all pre-consultation coordination on your behalf.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, flow cytometry results, imaging, prior treatment history, and molecular findings. The final consultation format and availability depend on the doctor's schedule and the hospital's protocols.
Yes. Prof. Zhu and his department at Peking University Cancer Hospital have been involved in more than 200 domestic and international new-drug lymphoma clinical trials, including studies on BTK inhibitors, bispecific antibodies, antibody-drug conjugates, and CAR-T cell therapies. CancerFax can assist with eligibility assessment for patients interested in trial access.
Prof. Zhu's department is involved in CAR-T cell therapy for eligible patients with relapsed or refractory B-cell lymphoma, including CD19-directed CAR-T approaches. Suitability for CAR-T therapy depends on individual patient eligibility. CancerFax can coordinate a case review to assess whether this approach may be appropriate.
Connect with Jun Zhu Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.